ARS Pharmaceuticals (SPRY) announced that California is now eligible for its neffyinSchools program. “One year ago, we envisioned a nationwide program that would give school nurses and staff the confidence to respond quickly to a severe allergic emergency, and we’re thrilled that California schools are now eligible to participate in this program,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “With neffy’s needle-free design, long shelf life and stability at temperature excursions of up to 122 degrees F, schools have an option that is compact, easy to use, easily disposable and is ready when needed. We look forward to adding more school communities in the future.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
- Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
- ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
- ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
- ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating